Medical devices, healthcare technology and the business of care
PMA approval · P190028

cobas HPV for use on the cobas 6800/8800 Systems

Roche Molecular Systems, Inc. · Decision date Apr 3, 2020

MEDTECHLEDGER EXPLANATIONP190028

What did the FDA approve?

FDA approved the original PMA for Roche Molecular Systems' cobas HPV test on the cobas 6800/8800 Systems. The device is a qualitative in vitro test for detecting Human Papillomavirus in clinician-collected cervical specimens placed in ThinPrep Pap Test PreservCyt Solution. It detects high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.

The stated indications cover routine cervical cancer screening per professional medical guidelines, including ASC-US cytology triage, co-testing with cytology, and HPV primary screening to assess cervical precancer and cancer risk. The source statement reports these intended uses but does not itself provide independent proof of safety or clinical effectiveness. No supplement type or reason is recorded.

FDA approval order statement

Approval for the cobas HPV for use on the cobas 6800/8800 Systems. cobas HPV for use on the cobas 6800/8800 Systems (cobas HPV) is a qualitative in vitro test for the detection of Human Papillomavirus in clinician-collected cervical specimens using an endocervical brush/spatula or broom and placed in the ThinPrep Pap Test PreservCyt Solution. This test detects the high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. cobas HPV is indicated for use for routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing (or adjunctive screen) with cytology, and HPV primary screening of women to assess the risk for cervical precancer and cancer. Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medical history, and other risk factors.
Regulatory pathway
Original PMA
Clinical specialty
Microbiology
Decision date
Apr 3, 2020

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P190028
Regulatory pathway
Premarket approval application
Product code
MAQ
Decision code
APPR
Decision date
Apr 3, 2020
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.

Product code
MAQ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P190028 received

    Application receipt date recorded by FDA.

  2. P190028 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P190028. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190028

Product / regulatory recordCompanyPathwayDecision dateSource
cobas HPVP190028/S026
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA

Explore the linked device profile

Other records with product code MAQ

Product / regulatory recordCompanyPathwayDecision dateSource
cobas HPVP100020/S066
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Alinity m HR HPVP230003/S019
Abbott Molecular, Inc.PMA supplementSep 2, 2026FDA
Abbott Molecular, Inc.PMA approvalNov 1, 2023FDA
Roche Molecular Systems, Inc.PMA approvalApr 19, 2011FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Molecular Systems, Inc.

Headquarters
Not reported
Brand website
roche.com
FDA applicant address
4300 Hacienda Dr., Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records